Comprehensive guides with safety triggers, contrarian views, research gaps, and practical protocol references.
A D-retro-inverso peptide that selectively kills senescent cells by disrupting the FOXO4-p53 survival interaction, triggering mitochondrial apoptosis in aged 'zombie' cells while sparing healthy tissue.
FOXO4-DRI breaks the molecular shield that keeps senescent cells alive. By freeing p53 from FOXO4 sequestration, it triggers selective apoptosis in aged cells, restoring kidney function, testosterone levels, and tissue vitality in preclinical models.
A selective ghrelin mimetic that triggers your pituitary to release growth hormone without touching cortisol, prolactin, or appetite.
Ipamorelin is a synthetic pentapeptide and the first truly selective growth hormone secretagogue. It binds the GHS-R1a receptor to trigger pulsatile GH release without the hormonal side-channel activation that defined earlier peptides like GHRP-6.
A synthetic GHRH analog that tells your pituitary to release its own growth hormone, not inject someone else's.
CJC-1295 is a 29-amino acid GHRH analog engineered to resist enzymatic breakdown. It stimulates endogenous GH pulses rather than flooding the system with synthetic hormone, offering a fundamentally different risk-benefit profile to direct HGH therapy.
A naturally occurring tripeptide locked inside your collagen that modulates 4,192 human genes, acts as a safe copper chaperone, and signals systemic repair, with plasma levels dropping 60% between ages 20 and 60.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine) is a naturally occurring tripeptide embedded in Type I collagen. Liberated during tissue injury, it acts as a master repair signal modulating 4,192 human genes (roughly one-third of the genome). It drives collagen synthesis, delivers copper safely to enzymes like Superoxide Dismutase via a unique square-planar pyramid configuration, and shows emerging potential in gut barrier repair (SIRT1/STAT3) and COPD reversal (127-gene signature). Plasma levels decline 60% by age 60. Clinical protocols use a biphasic 30-day cycle (1mg escalating to 2mg) with a mandatory 30-day rest. FDA Category 2 restricts legal compounding for systemic use. Contraindicated in active malignancies and Wilson's Disease.
A four-amino-acid peptide that activates telomerase, remodels chromatin, and restores melatonin synthesis from the pineal gland — addressing five hallmarks of aging simultaneously. The Russian clinical data spans 12–15 years. Independent Western replication barely exists.
Epitalon (AEDG) is a synthetic tetrapeptide modeled after the bovine pineal extract Epithalamin. It upregulates hTERT to activate telomerase, remodels heterochromatin to re-access silenced genes, restores endogenous melatonin production (160% increase in clinical trials), and demonstrated a 28% decrease in overall mortality over a 12-year human follow-up. A 2025 study revealed selective ALT pathway activation in cancer cells. The compound remains investigational — nearly all positive data originates from a single institutional network in St. Petersburg, and independent Western replication is virtually absent.
A 16-amino-acid mitochondrial messenger that mimics exercise at the cellular level — activating AMPK, reprogramming metabolism, and writing survival instructions directly into the nucleus. The science is striking. The stability problem is brutal.
MOTS-c is a mitochondrial-derived peptide (mitokine) that acts as an exercise mimetic through the Folate-AICAR-AMPK axis. It translocates to the nucleus under metabolic stress, enhances glucose uptake via GLUT4, promotes white-to-brown fat conversion, and reprograms immune cells toward anti-inflammatory phenotypes. A natural longevity variant (K14Q) exists in East Asian populations. Clinical translation is hampered by extreme instability (85–90% activity loss in 2–3 hours at room temperature) and a circulating half-life of only 1–2 hours.
An ACTH-derived heptapeptide that upregulates BDNF, modulates the Default Mode Network, and delivers 20-24 hours of neuroprotection per dose — without a single hormonal side effect.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) engineered from the ACTH(4-10) fragment. It upregulates Brain-Derived Neurotrophic Factor, inhibits enkephalinase, and suppresses neuroinflammation — delivering cognitive enhancement, stroke recovery support, and neuroprotection through a single intranasal molecule.
A tuftsin-derived heptapeptide that delivers benzodiazepine-level anxiety relief without sedation, dependence, or cognitive fog — while simultaneously boosting immune defence.
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) engineered from the immune peptide tuftsin. It allosterically modulates GABA-A receptors, stabilises endogenous enkephalins, and upregulates BDNF — delivering anxiolysis, cognitive enhancement, and immunomodulation in a single molecule.
A three-amino-acid peptide that bypasses the blood-brain barrier, enters the nucleus, and directly modulates gene expression for neuroprotection.
Pinealon is a synthetic tripeptide bioregulator (Glu-Asp-Arg) that penetrates the blood-brain barrier and nuclear membrane to directly influence chromatin remodeling, serotonin synthesis, and antioxidant defense in neurons.
A clear-eyed map of the peptides and nutritional adjuncts being used for attention and executive function — what the literature supports, what the FDA has banned, and where the biohacking consensus is running ahead of the data.
An evidence-based exploration of focus and ADHD peptides including Semax, Selank, Noopept, Cerebrolysin and their nutritional adjuncts — with the regulatory, retraction and translational-gap landscape that the biohacking coverage tends to leave out.
From Dihexa's synaptogenic hammer to Cerebrolysin's clinical track record — five realities of the peptide cognition frontier, and the regulatory minefield around them.
An evidence-based exploration of memory-management peptides including Dihexa, Semax, Selank, P21, and Cerebrolysin. We examine synaptogenic potency claims alongside oncogenic risk, the FDA's 2024 compounding ban, and where clinical evidence ends and biohacking speculation begins.
The peptide revolution promises to rewire your brain — but your immune system might have other plans.
An evidence-based exploration of neuroprotective peptides including GLP-1 receptor agonists, Selank, and Dihexa. We examine clinical promise alongside immunogenicity risks, grey-market purity concerns, and the thin line between neuroregeneration and oncogenic overstimulation.
The gland behind your breastbone has been shrinking since puberty — and taking your immune system with it.
Thymic involution is the progressive shrinkage of the thymus gland that accelerates immune aging. Thymic peptides like Thymosin β4 and Thymalin offer a regenerative approach to reversing this decline, with applications spanning cardiac repair, immune reconstitution, and even hair regrowth.
We are no longer blocking baldness -- we are rebooting the follicle from the inside out.
Emerging research reveals that hair loss is not simply a hormonal problem but a multi-layered signaling and metabolic failure. By targeting the CXXC5 molecular blockade, shifting stem-cell metabolism with MPC inhibitors, and rebuilding the follicle micro-environment with regenerative peptides, science is rewriting the rules of follicle restoration.
Our DNA is not a static blueprint of decline but a dynamic epigenetic landscape that can be re-tuned through precise molecular signaling.
Aging is a profound loss of transcriptional access, not just mechanical wear. Mitochondrial peptides like MOTS-c and SS-31, alongside epigenetic bioregulators such as Epitalon and Livagen, are rewriting the longevity playbook by restoring chromatin architecture and stabilizing the mitochondrial membrane. This protocol maps the frontier from deheterochromatinization to FDA-approved cristae repair.
Your body still has the blueprint for repair — peptides and pressurized oxygen are the missing construction crew.
Peptide therapy and hyperbaric oxygen work as architect and builder to unlock genomic repair mechanisms your body already possesses. From GHK-Cu's ability to reset 31.2% of human genes to MOTS-c's mitochondrial master switch, these tools move recovery science from symptom management to biological system optimization.
Your skin loses 1% of its collagen every year after 20—but peptide signaling can tell your fibroblasts to rebuild what time has taken.
A deep dive into the peptide protocols that restore skin elasticity from the cellular level up. From copper peptides that reactivate collagen genes to telomere-protective compounds that extend the lifespan of dermal cells, this is the science of reversing structural skin aging.
Mitochondria-derived peptides like SS-31 and MOTS-c are rewriting the rules of cellular energy — but the translational gap between mouse models and human performance remains wide open.
The mitochondrial revolution is moving beyond generic antioxidants toward precision peptides that stabilize the inner membrane and restore fading cellular signals. SS-31 tightens the elastic of the cell while MOTS-c acts as an exercise mimetic encoded in our own DNA — yet clinical reality checks remind us that promising preclinical data does not always survive the journey to the pharmacy.